Enanta Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US29251M1062

SecurityENTA / Enanta Pharmaceuticals, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership2,077 shares
Latest Disclosed Value $ 26,233
Citigroup Inc reports 46.06% increase in ownership of ENTA / Enanta Pharmaceuticals, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 2,077 shares of Enanta Pharmaceuticals, Inc. (US:ENTA) valued at $26,233 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 1,422 shares of Enanta Pharmaceuticals, Inc.. This represents a change in shares of 46.06% during the quarter. The current value of the position is $24,363 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,077 655 46.06 26 18.18 0.0000
2026-02-13 2025-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,422 -680 -32.35 22 -12.00 0.0000
2025-11-10 2025-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,102 -7,240 -77.50 25 -64.29 0.0000
2025-08-11 2025-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 9,342 -5,226 -35.87 71 -12.50 0.0000
2025-05-12 2025-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 14,568 -959 -6.18 80 -10.11 0.0000
2025-02-12 2024-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 15,527 850 5.79 89 -41.45 0.0001
2024-11-12 2024-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 14,677 10,119 222.01 152 157.63 0.0001
2024-08-12 2024-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 4,558 734 19.19 59 -10.61 0.0000
2024-05-10 2024-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,824 991 34.98 67 153.85 0.0000
2024-02-09 2023-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,833 2,286 417.92 27 333.33 0.0000
2023-12-06 2023-09-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 547 -39,683 -98.64 6 -99.30 0.0000
2023-11-09 2023-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 547 -39,683 6 0.0000
2023-08-10 2023-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 40,230 -10,190 -20.21 861 -57.80 0.0006
2023-05-11 2023-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 50,420 1,860 3.83 2,039 -9.78 0.0014
2023-02-09 2022-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 48,560 -21,634 -30.82 2,259 -37.96 0.0018
2022-11-10 2022-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 70,194 4,444 6.76 3,641 17.15 0.0026
2022-08-10 2022-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 65,750 37,249 130.69 3,108 53.18 0.0023
2022-05-12 2022-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 28,501 -24,797 -46.53 2,029 -49.10 0.0012
2022-02-10 2021-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 53,298 26,691 100.32 3,986 163.62 0.0021
2021-11-10 2021-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 26,607 -21,441 -44.62 1,512 -28.51 0.0009
2021-08-10 2021-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 48,048 -14,040 -22.61 2,115 -30.95 0.0013
2021-05-13 2021-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 62,088 10,551 20.47 3,063 41.22 0.0020
2021-02-11 2020-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 51,537 669 1.32 2,169 -6.87 0.0013
2020-11-12 2020-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 50,868 29,280 135.63 2,329 114.85 0.0015
2020-08-12 2020-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 21,588 4,819 28.74 1,084 25.75 0.0008
2020-05-12 2020-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 16,769 -13,842 -45.22 862 -54.42 0.0008
2020-02-12 2019-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 30,611 -7,954 -20.62 1,891 -18.39 0.0014
2019-11-08 2019-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 38,565 10,545 37.63 2,317 -2.03 0.0018
2019-08-12 2019-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 28,020 14,959 114.53 2,365 89.66 0.0019
2019-05-13 2019-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 13,061 -56,434 -81.21 1,247 -74.66 0.0012
2019-02-12 2018-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 69,495 62,367 874.96 4,922 708.21 0.0050
2018-11-13 2018-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 7,128 6,970 4,411.39 609 3,283.33 0.0005
2018-08-10 2018-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 158 -19,469 -99.19 18 -98.87 0.0000
2018-05-11 2018-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 19,627 -3,246 -14.19 1,588 18.33 0.0013
2018-02-12 2017-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 22,873 -1,609 -6.57 1,342 17.21 0.0011
2017-11-13 2017-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 24,482 -6,033 -19.77 1,145 4.28 0.0009
2017-08-11 2017-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 30,515 4,521 17.39 1,098 37.25 0.0010
2017-05-12 2017-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 25,994 -24,460 -48.48 800 -52.69 0.0007
2017-02-10 2016-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 50,454 32,822 186.15 1,691 260.55 0.0015
2016-11-10 2016-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 17,632 9,248 110.31 469 154.89 0.0004
2016-08-12 2016-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 8,384 -4,933 -37.04 184 -52.94 0.0002
2016-05-13 2016-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 13,317 10,552 381.63 391 325.00 0.0004
2016-02-12 2015-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,765 -6,854 -71.25 92 -73.56 0.0001
2015-11-13 2015-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 9,619 2,367 32.64 348 6.75 0.0003
2015-08-13 2015-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 7,252 178 2.52 326 50.23 0.0003
2015-05-14 2015-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 7,074 87 1.25 217 -39.04 0.0002
2015-02-17 2014-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 6,987 5,614 408.89 356 559.26 0.0003
2014-11-14 2014-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 1,373 464 51.05 54 38.46 0.0000
2014-08-14 2014-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 909 312 52.26 39 69.57 0.0000
2014-05-15 2014-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 597 -744 -55.48 23 -37.84 0.0000
2014-02-14 2013-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,341 1,335 22,250.00 37 0.0000
2013-11-14 2013-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 6 1 20.00 0 0.0000
2013-08-14 2013-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 5 5 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.